199 related articles for article (PubMed ID: 34069498)
21. Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.
Rickert EL; Oriana S; Hartman-Frey C; Long X; Webb TT; Nephew KP; Weatherman RV
Bioconjug Chem; 2010 May; 21(5):903-10. PubMed ID: 20420372
[TBL] [Abstract][Full Text] [Related]
22. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
23. FRET mechanism between a fluorescent breast-cancer drug and photodynamic therapy sensitizers.
Lahoz F; Scholz LE; Boto A; Díaz M
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Oct; 239():118498. PubMed ID: 32470814
[TBL] [Abstract][Full Text] [Related]
24. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.
Shim JS; Li RJ; Lv J; Head SA; Yang EJ; Liu JO
Cancer Lett; 2015 Jun; 362(1):106-15. PubMed ID: 25799952
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
Jameera Begam A; Jubie S; Nanjan MJ
Bioorg Chem; 2017 Apr; 71():257-274. PubMed ID: 28274582
[TBL] [Abstract][Full Text] [Related]
27. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
28. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
29. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.
Nelson ER
Methods Mol Biol; 2016; 1366():431-443. PubMed ID: 26585155
[TBL] [Abstract][Full Text] [Related]
30. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract][Full Text] [Related]
31. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
32. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
33. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
34. Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.
Silfen SL; Ciaccia AV; Bryant HU
Climacteric; 1999 Dec; 2(4):268-83. PubMed ID: 11910661
[TBL] [Abstract][Full Text] [Related]
35. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
36. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
37. A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy.
Zhang FL; Song MR; Yuan GK; Ye HN; Tian Y; Huang MD; Xue JP; Zhang ZH; Liu JY
J Med Chem; 2017 Aug; 60(15):6693-6703. PubMed ID: 28699738
[TBL] [Abstract][Full Text] [Related]
38. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
39. Selective estrogen receptor modulation: concept and consequences in cancer.
Jordan VC
Cancer Cell; 2004 Mar; 5(3):207-13. PubMed ID: 15050912
[TBL] [Abstract][Full Text] [Related]
40. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]